Welcome to our dedicated page for Amphastar Pharmaceuticals news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharmaceuticals stock.
Amphastar Pharmaceuticals develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal pharmaceutical products, and also sells active pharmaceutical ingredient products. Its finished products are distributed through group purchasing organizations, drug wholesalers, and drug retailers, with many used in hospital or urgent care settings.
Company news commonly covers quarterly financial results, product sales trends for therapies such as BAQSIMI®, Primatene MIST®, glucagon and epinephrine products, FDA approvals and launches, and spending on insulin, inhalation, and proprietary pipeline programs. Updates also include licensing activity, including AMP-110, a fully synthetic corticotropin compound for inflammatory and autoimmune conditions, as well as healthcare conference presentations and corporate communications.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will release fourth-quarter 2025 results after market close on Thursday, February 26, 2026 and will host a conference call the same day at 2:00 p.m. Pacific Time.
Investors can access the live call by dialing the provided toll-free or international numbers or via the company's Investors page at www.amphastar.com; a webcast replay will be posted within 24 hours.
Amphastar (NASDAQ:AMPH) entered an exclusive U.S. and Canada license with Nanjing Hanxin for AMP-110, a fully synthetic human ACTH analog targeting inflammatory and autoimmune conditions.
Key deal terms include a $2 million upfront payment, up to $14 million in development milestones, up to $75 million in sales milestones, and royalty payments to Hanxin not to exceed $7.5 million per year with a $60 million cumulative cap. Hanxin retains non-exclusive rights outside the U.S. and Canada. AMP-110 is in early-phase human studies with an early promising safety profile. The U.S. ACTH market exceeded $684 million in 2024.
Amphastar Pharmaceuticals (NASDAQ: AMPH) will present at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 at 2:15 PM PT. Jack Zhang, CEO and President, and Bill Peters, CFO, will deliver the presentation. A live webcast will be available at http://ir.amphastar.com and will remain accessible for 30 days after the presentation.
Amphastar focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and sells insulin active pharmaceutical ingredient products. Most finished products are used in hospital or urgent care settings and are distributed via group purchasing organizations and drug wholesalers.
Amphastar (NASDAQ: AMPH) announced FDA approval of its ANDA for teriparatide injection, USP 560 mcg/2.24 mL (250 mcg/mL) single‑patient‑use prefilled pen, judged bioequivalent and therapeutically equivalent to Eli Lilly's FORTEO.
Company plans a commercial launch by end of 2025, notes U.S. teriparatide sales of ~$585 million for the 12 months ended September 30, 2025 (IQVIA), and says the product is manufactured entirely in‑house at its U.S. facility.
Amphastar Pharmaceuticals (NASDAQ:AMPH) said Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will take part in an analyst-moderated fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Wednesday, December 3, 2025 at 2:00 PM ET.
The presentation will be available via webcast on Amphastar's investor website and will remain accessible for 30 days after the event.
Amphastar Pharmaceuticals (NASDAQ:AMPH) said its CFO Bill Peters and EVP of Corporate Administration Jacob Liawatidewi will participate in an analyst-moderated fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 19, 2025 at 3:30 PM GMT.
The event will be webcast and available for 30 days after the presentation. For access, visit the company investor website.
Amphastar Pharmaceuticals (NASDAQ: AMPH) reported Q3 2025 net revenues of $191.8M, GAAP net income of $17.4M or $0.37 per diluted share, and adjusted non-GAAP net income of $44.7M or $0.93 per diluted share for the three months ended September 30, 2025.
Key drivers included BAQSIMI sales of $53.6M (14% growth year‑over‑year) and the August 2025 launch of iron sucrose injection ($2.4M). GAAP results were affected by a $23.1M litigation provision included in general and administrative expenses and a $5.3M upfront R&D payment under an exclusive license with Nanjing Anji for three proprietary peptides. Operating cash flow for the nine months ended September 30, 2025 was $123.3M. The company will hold a conference call on November 6, 2025 at 2:00 p.m. PT.
Amphastar Pharmaceuticals (NASDAQ: AMPH) said it will release results for its third quarter of 2025, which ended September 30, 2025, after market close on Thursday, November 6, 2025. The company will hold a conference call that day at 2:00 p.m. Pacific Time to discuss results, accessible by toll-free dial-in and via webcast on the company Investors page, with a replay posted within 24 hours.
The release reiterates forward-looking statements about product sales, development, regulatory timing, manufacturing capacity expansion, and other future events, and points readers to Amphastar's SEC filings for risk factors and additional details.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its participation in the upcoming 2025 Wells Fargo Healthcare Conference. The company will be represented by CFO Bill Peters and SVP of Corp. Communication Dan Dischner in an analyst-moderated fireside chat.
The presentation is scheduled for Wednesday, September 3rd, 2025, at 12:45 pm ET. Investors can access the webcast through Amphastar's investor relations website at ir.amphastar.com, where it will remain available for 30 days after the presentation.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has entered into an exclusive licensing agreement with Nanjing Anji Biotechnology for three proprietary peptides in the US and Canada. The agreement includes an initial payment of $6 million ($0.75M earnest money + $5.25M upfront), with potential milestone payments reaching $453 million over the agreement's lifetime.
The licensed products include: 1) An endogenous peptide targeting multiple poorly treated cancers, 2) A novel peptide-docetaxel conjugate designed to improve taxane therapies, and 3) An anti-VEGFR peptide eye drop for wet age-related macular degeneration treatment. The agreement includes 5% royalty payments on net sales, capped at $60 million per Licensed Product.